Search

Displaying results 8231 - 8240 of 10000 in total
  1. Drug

    Zotiraciclib

    go.drugbank.com/drugs/DB16656
    Investigational

    Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma). … Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide

  2. Drug

    Inaxaplin

    go.drugbank.com/drugs/DB21521
    Investigational

    Inaxaplin is under investigation in clinical trial NCT06794996 (Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease).

  3. Drug

    Tofimilast

    go.drugbank.com/drugs/DB11681
    Investigational

    Tofimilast has been used in trials studying the treatment of Asthma and Pulmonary Disease, Chronic Obstructive.

  4. Drug

    Tofogliflozin

    go.drugbank.com/drugs/DB11824
    Investigational

    Tofogliflozin has been used in trials studying the treatment and prevention of Diabetes Mellitus Type 2.

  5. Drug

    IQP-0528

    go.drugbank.com/drugs/DB14888
    Investigational

    IQP-0528 is under investigation in clinical trial NCT03082690 (ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study).

  6. Drug

    Rivenprost

    go.drugbank.com/drugs/DB16315
    Investigational

    Rivenprost is under investigation in clinical trial NCT00296556 (Therapeutic Study of ONO-4819CD for Ulcerative Colitis).

  7. Drug

    DYN-101

    go.drugbank.com/drugs/DB17921
    Investigational

    DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.

  8. Drug

    Suvodirsen

    go.drugbank.com/drugs/DB17940
    Investigational

    Suvodirsen is an antisense oligonucleotide that has been investigated for the treatment of Duchenne muscular dystrophy.

  9. Drug

    CTX110

    go.drugbank.com/drugs/DB18626
    Investigational

    CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.

  10. Drug

    Leflutrozole

    go.drugbank.com/drugs/DB19047
    Investigational

    Leflutrozole is under investigation in clinical trial NCT02908074 (A 6 Month Safety Extension Study of MBGS205).